Nilotinib: a novel, selective tyrosine kinase inhibitor.

Nilotinib: a novel, selective tyrosine kinase inhibitor.

Item
http://www.wikidata.org/entity/Q37855073
The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells.High-grade KIT-negative sarcoma of the small bowel in a patient with chronic myeloid leukemia receiving long-term tyrosine kinase inhibitors.Imatinib mesylate: past successes and future challenges in the treatment of gastrointestinal stromal tumors.A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib.Small molecule kinase inhibitors block the ZAK-dependent inflammatory effects of doxorubicin.Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors.Reversing multidrug resistance by tyrosine kinase inhibitorsClinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.Label-free visualization of nilotinib-functionalized gold nanoparticles within single mammalian cells by C60- SIMS imaging.Driving forces behind the past and future emergence of personalized medicine.A novel tyrosine kinase inhibitor AMN107 (nilotinib) normalizes striatal motor behaviors in a mouse model of Parkinson's disease.Evaluating the Impact of a Switch to Nilotinib on Imatinib-Related Chronic Low-Grade Adverse Events in Patients With CML-CP: The ENRICH Study.The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia.Identification of abelson tyrosine kinase inhibitors as potential therapeutics for Alzheimer's disease using multiple e-pharmacophore modeling and molecular dynamics.Radiosynthesis of the anticancer nucleoside analogue Trifluridine using an automated 18F-trifluoromethylation procedure.Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.
P2860

Nilotinib: a novel, selective tyrosine kinase inhibitor.

Item
http://www.wikidata.org/entity/Q37855073
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@en
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@nl
type
label
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@en
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@nl
prefLabel
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@en
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@nl
P1433
P1476
P2860
P304
P31
P356
P478
P50
P577
P698
P932
P356
P1433
P1476
Nilotinib: a novel, selective tyrosine kinase inhibitor.
@en
P2860
P304
P31
P356
10.1053/J.SEMINONCOL.2011.01.016
P478
P50
P577
P698
P932